PFS
BOLT icon

Prospera Financial Services’s Bolt Biotherapeutics BOLT Stock Holding History

Prospera Financial Services’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-210
Closed -$12K – 1730
2022
Q1 		$12K Buy
+210
New +$14.1K ﹤0.01% 1943

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Prospera Financial Services's BOLT Position: Q2 2022 in Review

Prospera Financial Services sold out of Bolt Biotherapeutics (BOLT) in Q2 2022, closing a stake of 210 shares — an estimated $12K sold.

Prospera Financial Services first reported a position in BOLT in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2022.

  • Prospera Financial Services reported no remaining Bolt Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 210 Bolt Biotherapeutics shares in Q2 2022, an estimated $12K.
  • Prospera Financial Services first reported a position in Bolt Biotherapeutics in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Bolt Biotherapeutics position peaked at $12K in Q1 2022.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.